TNFRSF8 and diffuse large B-cell lymphoma: -Not FDA approved for R/R DLBCL but used occasionally off label when CD30 is expressed and especially in patients unfit for chemotherapy.-Brentuximab + lenalidomide + rituximab regimen is being compared against placebo + rituximab + lenalidomide in a phase 3 trial (ECHELON-3) of R/R DLBCL patients